Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with short-course chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
ChiCTR2600128416Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in rectal adenocarcinoma, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600128416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128416.